Dec 13 (Reuters) - Aurinia Pharmaceuticals Inc AUP.TO
* Aurinia confirms receipt of FDA end of phase 2 meeting minutes
* Trial on track to commence in Q2 2017
* Single phase 3 clinical trial to be conducted with 23.7 mg bid voclosporin for treatment of active lupus nephritis
* Aurinia believes phase 3 clinical trial will support a new drug application (nda) submission Source text for Eikon: ID:nBw5KmmC9a Further company coverage: AUP.TO
(Bangalore.newsroom@thomsonreuters.com)